Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
| Autor: | Raquel López‐Vilella, Silvia Lozano‐Edo, Patricia Arenas Martín, Pablo Jover‐Pastor, Meryem Ezzitouny, José Sorolla Romero, María Calvo Asensio, Julia Martínez‐Solé, Borja Guerrero Cervera, José Carlos Sánchez Martínez, Víctor Donoso Trenado, Ignacio Sánchez‐Lázaro, Luis Martinez Dolz, Luis Almenar Bonet |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Ferritin
Iron deficiency Stroke Volume Heart failure Original Articles Preserved ejection fraction Ferric carboxymaltose Ferric Compounds Ventricular Function Left Reduced ejection fraction RC666-701 Humans Diseases of the circulatory (Cardiovascular) system Original Article Maltose Cardiology and Cardiovascular Medicine Retrospective Studies |
| Zdroj: | ESC Heart Failure, Vol 9, Iss 1, Pp 133-145 (2022) ESC Heart Failure |
| ISSN: | 2055-5822 |
| Popis: | Aims Heart failure (HF) is a proinflammatory disease often associated with the onset of iron deficiency (ID). ID alters mitochondrial function, reducing the generation of cellular energy in skeletal muscle and cardiomyocytes. This study aimed to analyse the response of patients with HF to intravenous iron administration according to the type of HF: preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF). Methods and results We conducted a retrospective, single‐centre study of 565 consecutive outpatients diagnosed with HF, recruited over 5 years, who were given intravenous ferric carboxymaltose (FCM) for the treatment of ID [defined as ferritin 0.05). Conclusions Intravenous iron administration appeared to improve ejection fraction and cardiac functional status in outpatients with ID and HF with both preserved and reduced ejection fraction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text